Valuation : MIRA Pharmaceuticals, Inc.

Market Cap 32.1M 27.6M 25.96M 23.7M 44.32M 3.04B 44.47M 308M 119M 1.55B 121M 118M 4.95B P/E 2024
-2.24x
P/E 2025 -1.12x
Enterprise Value 21.64M 18.61M 17.5M 15.98M 29.88M 2.05B 29.98M 208M 80.22M 1.05B 81.26M 79.49M 3.34B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
69.42%
Yield 2024 *
-
Yield 2025 -
1 day+3.27%
1 week-0.83%
Current month-0.83%
1 month+3.22%
3 months-23.62%
6 months-34.16%
Current year-49.42%
1 week 0.73
Extreme 0.7313
0.93
1 month 0.71
Extreme 0.7101
1.1
Current year 0.6
Extreme 0.6
1.54
1 year 0.6
Extreme 0.6
2.45
3 years 0.51
Extreme 0.51
6.48
5 years 0.51
Extreme 0.51
7.98
10 years 0.51
Extreme 0.51
7.98
Manager TitleAgeSince
Chief Executive Officer 48 2023-03-31
Director of Finance/CFO 43 2026-06-05
Director TitleAgeSince
Chairman 48 2024-03-12
Director/Board Member 44 2024-03-12
Director/Board Member 45 2024-03-12
Date Insider Type Main position Quantity % Market Cap. Importance
3/30/26 Free

Chief Executive Officer

83,500 0.1994%
12/31/25 Free

Chief Executive Officer

5,120,955 12.2288%
10/1/25 Free

Chief Executive Officer

2,685,456 16.2157%
Change 5-day change 1-year change 3-year change Capi.($)
+3.27%-0.83%-45.44%-87.35% 32.1M
-0.38%-0.99%+42.69%+100.85% 67.82B
-2.71%-0.71%+35.89%+81.43% 63.22B
-0.31%+3.67%-12.96%+374.95% 27.58B
+0.86%+2.12%-7.74%-13.34% 26.06B
+0.37%-1.66%+24.83%+13.96% 25.38B
-1.11%+0.90%+22.24%-18.50% 19.89B
+1.15%-5.02%+219.82%+379.02% 17.4B
-1.10%-0.98%-7.88%+521.00% 14.95B
-0.20%+8.00%+55.78%+167.98% 14.62B
Average -0.02%+1.07%+32.72%+152.00% 27.7B
Weighted average by Cap. -0.70%+0.48%+36.83%+140.12%

Financials

2024 2025
Net sales - -
Net income -7.85M -6.75M -6.35M -5.8M -10.84M -743M -10.88M -75.31M -29.11M -380M -29.49M -28.85M -1.21B -10.44M -8.98M -8.45M -7.71M -14.42M -988M -14.47M -100M -38.71M -506M -39.22M -38.36M -1.61B
Net Debt -2.83M -2.44M -2.29M -2.09M -3.91M -268M -3.92M -27.17M -10.5M -137M -10.64M -10.41M -437M -10.46M -8.99M -8.46M -7.72M -14.44M -989M -14.49M -100M -38.77M -506M -39.27M -38.41M -1.61B
Logo MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
Employees
-
Date Price Change Volume
26-09-04 US$0.7638 +3.27% 338,530
26-09-03 US$0.7396 -12.94% 494,946
26-09-02 US$0.8495 -1.22% 581,841
26-09-01 US$0.8600 +11.66% 29,281,096

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MIRA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!